Targeting the Helicobacter pylori–Gastric Cancer Axis with Nanomaterials: From Infection Control to Tumor-Directed Therapy
- 1Department of Immunology and Infectious Biology, Institute of Microbiology, Biotechnology and Immunology, Faculty of Biology and Environmental Protection, University of Lodz, 91-278 Lodz, Poland
- 2BioMedChem Doctoral School of the University of Lodz and Lodz Institutes of the Polish Academy of Sciences, University of Lodz, 91-278 Lodz, Poland
Abstract
Helicobacter pylori (H. pylori) infection promotes persistent mucosal inflammation, oxidative stress, epithelial injury, immune dysregulation, and progressive remodeling of the gastric microenvironment, thereby increasing the risk of gastric cancer (GC). Although H. pylori eradication and GC therapy are usually treated as separate clinical problems, they are linked by a continuum of pathogenic processes. Nanomaterial-based therapeutic systems may help overcome different barriers on this axis by improving drug stability and delivery, facilitating transport through mucus and biofilms, and enabling host-directed immunomodulation. This review focuses on polymeric, lipid-based, inorganic, hybrid, and stimuli-responsive approaches relevant to the management of H. pylori infection and the treatment of GC, emphasizing how carrier design can be adapted to different disease stages. Selected chitosan-based particles and functionalized poly(lactic acid) systems are discussed as examples of stage-adapted delivery strategies across the infection–cancer continuum. This review also describes three-dimensional and infection-associated GC models as tools for assessing nanoparticle penetration and therapeutic responses under more physiologically relevant conditions. Stage-adapted interventions are considered as distinct or potentially sequential approaches, rather than as a single validated platform combining bacterial eradication, inflammation control, mucosal repair, and anticancer therapy.
Related
- CRISPR/Cas9-Directed PEPD Targeting Is Associated with Reduced PEPD Activity and an Exploratory p53- and Apoptosis-Related Protein Pattern in MCF7 Breast Cancer Cells
- Tricin‐Loaded Liposomes as a Passive Targeting Nanodelivery System for Enhanced Gastric Cancer Therapy
- Application and Research of Laser Manufacturing Technology in Nanomaterials
- Immobilization of Pepsin on Different Nanomaterials and Its Application in Obtaining Bioactive Peptides
- First-Principles Investigations of Low-Dimensional Nanomaterials (2nd Edition)
BibTeX
@article{jaroniek2026targeting,
title = {{Targeting the Helicobacter pylori–Gastric Cancer Axis with Nanomaterials: From Infection Control to Tumor-Directed Therapy}},
author = {Patrycja Jaroniek and Maria Połomska and Magdalena Chmiela and Weronika Gonciarz},
journal = {Molecules},
year = {2026},
month = nov,
doi = {10.3390/molecules31213924},
url = {https://www.mdpi.com/1420-3049/31/21/3924},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Targeting the Helicobacter pylori–Gastric Cancer Axis with Nanomaterials: From Infection Control to Tumor-Directed Therapy
AU - Patrycja Jaroniek
AU - Maria Połomska
AU - Magdalena Chmiela
AU - Weronika Gonciarz
PY - 2026
DA - 2026/11/01
JO - Molecules
DO - 10.3390/molecules31213924
UR - https://www.mdpi.com/1420-3049/31/21/3924
AB - Helicobacter pylori (H. pylori) infection promotes persistent mucosal inflammation, oxidative stress, epithelial injury, immune dysregulation, and progressive remodeling of the gastric microenvironment, thereby increasing the risk of gastric cancer (GC). Although H. pylori eradication and GC therapy are usually treated as separate clinical problems, they are linked by a continuum of pathogenic processes. Nanomaterial-based therapeutic systems may help overcome different barriers on this axis by improving drug stability and delivery, facilitating transport through mucus and biofilms, and enabling host-directed immunomodulation. This review focuses on polymeric, lipid-based, inorganic, hybrid, and stimuli-responsive approaches relevant to the management of H. pylori infection and the treatment of GC, emphasizing how carrier design can be adapted to different disease stages. Selected chitosan-based particles and functionalized poly(lactic acid) systems are discussed as examples of stage-adapted delivery strategies across the infection–cancer continuum. This review also describes three-dimensional and infection-associated GC models as tools for assessing nanoparticle penetration and therapeutic responses under more physiologically relevant conditions. Stage-adapted interventions are considered as distinct or potentially sequential approaches, rather than as a single validated platform combining bacterial eradication, inflammation control, mucosal repair, and anticancer therapy.
SN - 1420-3049
ER -